πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 423 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12325708

Adenosine 2 receptor antagonists

Nektar Therapeutics Β· Granted Tue Jun 10 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 05 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12324828

Conjugates of a factor VIII moiety having an oxime-containing linkage

Nektar Therapeutics Β· Granted Tue Jun 10 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 05 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12247059

Conjugates of an IL-2 moiety and a polymer

Nektar Therapeutics Β· Granted Tue Mar 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12233104

Combination of an IL-2RBETA-selective agonist and a long-acting IL-15 agonist

Nektar Therapeutics Β· Granted Tue Feb 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12214045

Multi-arm polymer conjugates of TLR agonist compounds and related immunotherapeutic treatm

Nektar Therapeutics Β· Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12054553

Immunotherapeutic tumor treatment method

Nektar Therapeutics Β· Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12036283

Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions an

Nektar Therapeutics Β· Granted Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12030940

Immunotherapeutic tumor treatment method

Nektar Therapeutics Β· Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12016952

Methods of preparing a monodisperse oligo(ethylene glycol) reagent composition

Nektar Therapeutics Β· Granted Tue Jun 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11932726

Method of making releasable polymeric reagents

Nektar Therapeutics Β· Granted Tue Mar 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11834553

Alkoxylation methods

Nektar Therapeutics Β· Granted Tue Dec 05 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11813241

Multi-arm polymeric prodrug conjugates of taxane-based compounds

Nektar Therapeutics Β· Granted Tue Nov 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11744898

Multi-arm polymer conjugates of TLR agonist compounds and related immunotherapeutic treatm

Nektar Therapeutics Β· Granted Tue Sep 05 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 31 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11672776

Multi-arm polymeric alkanoate conjugates

Nektar Therapeutics Β· Granted Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11634540

Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method

Nektar Therapeutics Β· Granted Tue Apr 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11628205

Conjugates of a factor VIII moiety having an oxime-containing linkage

Nektar Therapeutics Β· Granted Tue Apr 18 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11612662

Multi-arm polymeric prodrug conjugates of pemetrexed-based compounds

Nektar Therapeutics Β· Granted Tue Mar 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11464788

Oligomer-corticosteroid conjugates

Nektar Therapeutics Β· Granted Tue Oct 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11446385

Polymer derivatives having particular atom arrangements

Nektar Therapeutics Β· Granted Tue Sep 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11419943

Polymer-sunitinib conjugates

Nektar Therapeutics Β· Granted Tue Aug 23 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11406618

Polymer-des-ethyl sunitinib conjugates

Nektar Therapeutics Β· Granted Tue Aug 09 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11318164

Immunotherapeutic treatment method using an interleukin-2 receptor beta-selective agonist

Nektar Therapeutics Β· Granted Tue May 03 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11266742

Conjugates having a degradable linkage and polymeric reagents useful in preparing such con

Nektar Therapeutics Β· Granted Tue Mar 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11241415

N-methyl-N-(1-phenyl-2-(1-pyrrolidinyl)ethyl)-2-aminophenylacetamide derivatives agonists

Nektar Therapeutics Β· Granted Tue Feb 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted